AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Total debt
AbbVie Inc.'s total debt at the end of fiscal 2025 was $67.5B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $70.8B. Over the past ten years it has ranged from $31.7B (fiscal 2015) to $86.1B (fiscal 2020); the current reading is higher than 82% of that period. AbbVie Inc. ranks 1st of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $67.5B | 0.52% |
| FY2024 | $67.1B | 13.07% |
| FY2023 | $59.4B | (6.14%) |
| FY2022 | $63.3B | (17.49%) |
| FY2021 | $76.7B | (10.89%) |
| FY2020 | $86.1B | 28.97% |
| FY2019 | $66.7B | 65.54% |
| FY2018 | $40.3B | 7.87% |
| FY2017 | $37.4B | 1.43% |
| FY2016 | $36.8B | 16.33% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $70.8B | (2.79%) |
| Mar 2026 | $72.9B | 7.94% |
| Dec 2025 | $67.5B | (1.81%) |
| Sep 2025 | $68.7B | (2.47%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABBV AbbVie Inc. | $70.8B |
| PFE Pfizer Inc. compare | $63.2B |
| AMGN Amgen Inc. compare | $57.3B |
| LLY Eli Lilly and Company compare | $54.9B |
| MRK Merck & Co., Inc. compare | $51.1B |
| NVS Novartis AG compare | $47.1B |
| JNJ Johnson & Johnson compare | $37.3B |
| AZN AstraZeneca PLC compare | $29.5B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement